Fisher & Paykel Healthcare

What Fisher & Paykel Healthcare does

Fisher & Paykel Healthcare is a New Zealand-based designer, manufacturer and marketer of medical devices focused on respiratory care, surgery and the treatment of obstructive sleep apnea. The company was founded in 1969 on the back of its first prototype respiratory humidifier and has built a 50+ year specialty around heated humidification and flow therapy, with flagship platforms including the F&P 850 and F&P 950 humidification systems, the Airvo 2 and Airvo 3 high flow therapy systems delivering Optiflow nasal high flow therapy (up to 70 L/min), an extensive homecare PAP mask portfolio (Nova Nasal, Nova Micro, Evora Full, Vitera, Simplus, Brevida, Eson 2, Solo and others), the SleepStyle CPAP device, and a neonatal line (Neopuff T-piece resuscitator, Bubble CPAP, Optiflow Junior 2, FlexiTrunk). Supporting software includes the myMask app with camera-based facial sizing, InfoSmart and InfoSmart Web for remote patient monitoring, and the VentilO dead-space analysis app.

The business generates revenue primarily through hardware sales of respiratory devices, humidification systems, CPAP masks and accessories to hospitals, healthcare providers and homecare patients globally. Commercialization is conducted via a dedicated enterprise field sales force engaging hospitals and clinicians directly, complemented by authorized CPAP dealers and DME providers for homecare, sleep lab channels, and clinical education assets such as the F&P Education Hub and The Incubator podcast partnership. Pricing is not publicly disclosed and is established through direct quotes and channel partners; medical devices are prescription-only.

For FY ended March 2025 the company reported record operating revenue of NZ$2.02 billion (16% growth, the first time exceeding NZ$2 billion), net profit after tax of NZ$377.2 million (up 43%), operating cash flow of NZ$549 million, and R&D investment of NZ$226.9 million, with FY2026 revenue guidance of NZ$2.15-2.25 billion. Operations span more than 120 countries with a headcount in the 5,001-10,000 range, and the company is publicly traded on the NZX under ticker FPH.

Name

Fisher & Paykel Healthcare

Legal name

Fisher & Paykel Healthcare Limited

Website

https://fphcare.com

Company type

Public

Founded year

1969

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fisher & Paykel Healthcare is a New Zealand-based medical device company that designs, manufactures and markets heated humidification systems, nasal high flow therapy devices (Optiflow, Airvo), CPAP masks and devices, and neonatal respiratory products for hospitals, homecare sleep apnea patients and NICUs across 120+ countries.

Ownership category

akta.pro rank

Product category

Respiratory Care Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)

akta.pro secondary industry

Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)

Keywords

• Respiratory care devices
• Medical humidification systems
• Nasal high flow therapy
• Neonatal respiratory support
• Sleep apnea treatment

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of respiratory care devices, humidification systems, CPAP masks, and accessories to hospitals, healthcare providers, and homecare patients globally

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Fisher & Paykel Healthcare designs, manufactures, and markets heated humidification systems, nasal high flow therapy devices, CPAP machines, masks, and neonatal respiratory care products. The portfolio spans hospital-based acute care (Airvo systems, F&P 950/850 humidifiers, NIV masks, neonatal resuscitators) and homecare for chronic respiratory conditions and obstructive sleep apnea (CPAP devices, myAirvo, mask range). Software tools such as the myMask app, InfoSmart Web, and VentilO app support mask fitting, remote patient monitoring, and clinical analysis.

Product overview

Fisher & Paykel Healthcare offers an integrated respiratory care portfolio built around core humidification technology (F&P 850 and 950 Systems) supporting multiple therapy applications. The hospital portfolio includes Airvo high flow therapy systems (Airvo 2, Airvo 3) delivering Optiflow nasal high flow therapy, invasive and noninvasive ventilation masks (Visairo, Nivairo), and neonatal/infant respiratory solutions (Neopuff, Bubble CPAP, Optiflow Junior 2, FlexiTrunk). The homecare portfolio centers on sleep apnea treatment with extensive PAP mask options (Nova Nasal, Nova Micro, Evora Full, Vitera, Simplus, Brevida, Eson 2, and others), CPAP devices (SleepStyle), and humidified high flow systems (myAirvo 2, myAirvo 3). Software solutions include the myMask app for mask selection and sizing, InfoSmart/InfoSmart Web for remote patient monitoring, and VentilO app for analyzing respiratory dead space. The products are supported by clinical education resources and work across hospital and home care settings.

Differentiator

Problem solved

Functional benefit

Brands

• Airvo: High flow therapy system brand including Airvo 2 and Airvo 3 systems
• Optiflow
• myMask
• F&P Education Hub
• F&P Solo
• F&P SleepStyle
• F&P Evora
• F&P Vitera
• F&P Simplus
• F&P 950 System
• F&P 850 System
• Neopuff
• Evaqua
• FlexiTrunk
• myAirvo
• AirSpiral
• RollFit
• SwingFit
• VentiCool
• Dynamic Support Technology

Products and services

• F&P Airvo 3
• F&P Airvo 2
• F&P 950 System
• F&P 850 System
• F&P myAirvo 2
• F&P SleepStyle
• F&P myMask App
• F&P InfoSmart Web
• F&P Evora Full
• F&P Vitera
• F&P Nova Nasal
• F&P Nova Micro
• F&P Solo
• F&P Visairo RT075/RT076/RT077
• F&P Nivairo RT045/RT046/RT047
• Optiflow 3S Nasal Cannula
• Optiflow+ Nasal Cannula
• F&P Neopuff T-Piece Resuscitator
• Optiflow Junior 2 Nasal Cannula
• F&P Bubble CPAP System
• VentilO App

Quantifiable outcome

• Record operating revenue of NZ$2.02 billion for FY2025, first time exceeding NZ$2 billion
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature12 records

Partnerships

Three partnerships are on record, tiered minor and core.

• SunergiseminorOthers · 16 June 2026Sunergise completed and switched on a 5.3 MW grid-connected rooftop solar system at Fisher & Paykel Healthcare's Auckland campus, the largest rooftop solar installation in New Zealand. Spanning approximately 70,000 m2 across two buildings with 8,273 solar modules, the project was delivered under a Power Purchase Agreement model with no upfront capital cost to Fisher & Paykel Healthcare.
• The IncubatorcoreStrategic or Co-development PartnerGlobal podcast platform partnership for expert-led neonatal care discussions and education. Fisher & Paykel Healthcare collaborates with The Incubator to share clinical expertise and innovations in neonatal respiratory care through podcast series featuring neonatal experts from leading institutions.
• Temple University HospitalcoreStrategic or Co-development PartnerTemple University Hospital leads the multi-center HiFlo COPD clinical trial evaluating the effect of nasal high flow therapy in COPD patients in the home setting. Fisher & Paykel Healthcare supports the trial with their myAirvo system, advancing research into home-based respiratory therapy for chronic conditions.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ResMed: ResMed is the global #1 in OSA therapy with dominant CPAP devices (AirSense), AirFit masks and the myAir patient app — directly competing with FPH's SleepStyle CPAP, full mask portfolio (Nova, Evora, Vitera) and myMask app across both hospital respiratory and home sleep markets.
• Vyaire Medical: Vyaire Medical focuses on respiratory diagnostics, ventilation circuits, and airway management consumables — directly comparable to F&P's Evaqua/AirSpiral breathing circuits and Optiflow interfaces sold to hospital anesthesia and respiratory therapy departments.
• Hamilton Medical: Hamilton Medical manufactures ICU ventilators, high-flow therapy devices and NIV interfaces (such as those used in hospital settings) — competing head-to-head with F&P's F&P 950/Airvo 3 and NIV mask portfolio in adult acute respiratory care.
• Koninklijke Philips (Respironics): Philips Respironics is a historical leader in CPAP/sleep (DreamStation, DreamWear) and hospital NIV; while its 2021 recall weakened its position, it remains a direct competitor in F&P's core sleep apnea and hospital NIV mask categories.

Emerging players

• BMC Medical: BMC Medical is a fast-growing Chinese CPAP and mask competitor with strong distribution in Asia and emerging markets; it represents an emerging low-cost threat in the OSA category where FPH also competes with its SleepStyle and mask portfolio.
• Teleflex Incorporated: Teleflex markets respiratory and anesthesia products (e.g., Hudson RCI nebulizers, oxygen therapy consumables) that overlap with FPH's interfaces and circuits in hospital respiratory care, though Teleflex is broader med-surg.

Broad incumbents

• Getinge: Getinge's Maquet/Servo-i line competes with F&P humidification/NIV solutions in hospital critical care, and its broader surgical and ICU portfolio makes it an established incumbent in shared hospital accounts with FPH.
• Drägerwerk: Dräger is a broad medical-safety incumbent whose anesthesia, ventilation and patient-monitoring portfolio (including Babyleo neonatal devices) overlaps directly with F&P's hospital respiratory, anesthesia gas delivery and neonatal respiratory segments.
• Medtronic plc: Medtronic is a broad medtech incumbent with respiratory and patient-monitoring adjacencies (including Puritan Bennett ventilation) that compete in the same hospital respiratory accounts as F&P's ICU humidification and NIV portfolio.

Others

• ResMed (Propeller Health): ResMed's connected-health and software platforms (including myAir and AirView) are highly comparable to FPH's myMask and InfoSmart data platforms — adjacent ecosystem participants in OSA patient engagement and compliance monitoring.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/fphcare
• Xx.com/fphcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fisher & Paykel Healthcare